Metropolitan Life Insurance Company (MetLife)’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-6,042	Closed	-$127K	–	2724
2015 Q3	$127K	Sell	6,042 -347	-5%	-$11.9K	﹤0.01%	2540
2015 Q2	$316K	Sell	6,389 -2,897	-31%	-$173K	﹤0.01%	2081
2015 Q1	$727K	Hold	9,286	–	–	0.01%	1376
2014 Q4	$563K	Hold	9,286	–	–	﹤0.01%	1682
2014 Q3	$396K	Buy	9,286 +394	+4%	+$21.2K	﹤0.01%	1870
2014 Q2	$550K	Hold	8,892	–	–	﹤0.01%	1770
2014 Q1	$578K	Buy	8,892 +1,259	+16%	+$85.2K	﹤0.01%	1705
2013 Q4	$430K	Buy	7,633 +96	+1%	+$5.39K	﹤0.01%	1913
2013 Q3	$463K	Hold	7,537	–	–	﹤0.01%	1804
2013 Q2	$441K	Buy	+7,537	New	+$464K	﹤0.01%	1775

Other funds holding OREX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s OREX Position: Q4 2015 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2015, closing a stake of 6,042 shares — an estimated $127K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in OREX in Q2 2013 and held it in 10 quarters. The position peaked at $727K in Q1 2015. 121 funds tracked by Wall St. Rank hold OREX as of Q4 2015.

Metropolitan Life Insurance Company (MetLife) reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 6,042 Orexigen Therapeutics, Inc. shares in Q4 2015, an estimated $127K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 10 quarters.
Metropolitan Life Insurance Company (MetLife)'s Orexigen Therapeutics, Inc. position peaked at $727K in Q1 2015.
121 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2015.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2015, filed 11 Feb 2016.